5-Arylaminouracil Derivatives: New Inhibitors of<i>Mycobacterium tuberculosis</i>
作者:Elena Matyugina、Mikhail Novikov、Denis Babkov、Alexander Ozerov、Larisa Chernousova、Sofia Andreevskaya、Tatiana Smirnova、Inna Karpenko、Alexander Chizhov、Pravin Murthu、Stefan Lutz、Sergei Kochetkov、Katherine L. Seley-Radtke、Anastasia L. Khandazhinskaya
DOI:10.1111/cbdd.12603
日期:2015.12
Three series of 5‐arylaminouracil derivatives, including 5‐(phenylamino)uracils, 1‐(4′‐hydroxy‐2′‐cyclopenten‐1′‐yl)‐5‐(phenylamino)uracils, and 1,3‐di‐(4′‐hydroxy‐2′‐cyclopenten‐1′‐yl)‐5‐(phenylamino)uracils, were synthesized and screened for potential antimicrobial activity. Most of compounds had a negative effect on the growth of the Mycobacterium tuberculosis H37Rv strain, with 100% inhibition observed at concentrations between 5 and 40 μg/mL. Of those, 1‐(4′‐hydroxy‐2′‐cyclopenten‐1′‐yl)‐3‐(4‴‐hydroxy‐2‴‐cyclopenten‐1‴‐yl)‐5‐(4″‐butyloxyphenylamino)uracil proved to be the most active among tested compounds against the M. tuberculosis multidrug‐resistant strain MS‐115 (MIC90 5 μg/mL). In addition, the thymidylate kinase of M. tuberculosis was evaluated as a possible enzymatic target.